WUXI XDC (02268) net profit doubles in 2025, shareholders' profit after adjustment is about 15.59 billion yuan, an increase of 69.9% year-on-year.

WUXI XDC (02268) announced its performance for the year 2025, with revenue of approximately 5.944 billion yuan, a year-on-year increase of 46.7%; gross profit of approximately 2.139 billion yuan, a year-on-year increase of 72.5%; the Company's attributable adjusted net profit was approximately 1.559 billion yuan, a year-on-year increase of 69.9%; and net profit increased by 38.4% year-on-year to 1.48 billion yuan. The total value of unfinished orders for the Group also increased by 50.3% from 991 million USD as of December 31, 2024 to 1.489 billion USD as of December 31, 2025. The announcement stated that the Group's CRDMO business continued to show strong momentum in 2024 and 2025, with ongoing expansion and increasing demand from global customers for its services. As of December 31, 2025, the Group has empowered a total of 643 customers globally with its comprehensive CRDMO capabilities and facilities equipped with "one-stop" functions from drug discovery to commercialization. The Group has successfully obtained a total of 18 PPQ (Process Validation) projects and 1 commercialization project. The increase in revenue is mainly due to (i) the continued active development of the global Antibody-Drug Conjugates (ADC) and broader biopharmaceutical conjugates market, driving an increase in the number of customers and projects; (ii) the Group's solid position as a leading ADC CRDMO service provider, driving an increase in its market share; and (iii) the steady progress of the Group's projects towards later stages (which typically generate higher contract values).